Rozengurt E, Eibl G. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. World J Gastroenterol 2019; 25(15): 1797-1816 [PMID: 31057295 DOI: 10.3748/wjg.v25.i15.1797]
Corresponding Author of This Article
Guido Eibl, MD, Director, Professor, Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, 72-236 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095, United States. geibl@mednet.ucla.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2019; 25(15): 1797-1816 Published online Apr 21, 2019. doi: 10.3748/wjg.v25.i15.1797
Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development
Enrique Rozengurt, Guido Eibl
Enrique Rozengurt, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, United States
Enrique Rozengurt, Guido Eibl, CURE: Digestive Diseases Research Center, Los Angeles, CA 90095, United States
Guido Eibl, Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, United States
Author contributions: Eibl G and Rozengurt E contributed equally to writing and revising the manuscript.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Guido Eibl, MD, Director, Professor, Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, 72-236 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095, United States. geibl@mednet.ucla.edu
Telephone: +1-310-7949577 Fax: +1-310-2062472
Received: February 6, 2019 Peer-review started: February 6, 2019 First decision: March 5, 2019 Revised: March 20, 2019 Accepted: March 24, 2019 Article in press: March 25, 2019 Published online: April 21, 2019
Core Tip
Core tip: The identification of signaling networks that underlie risk factor promoted pancreatic cancer development and progression is of paramount importance to prevent or intercept this lethal disease. Accumulating evidence suggests that several core signaling pathways downstream of oncogenic Kras, augmented by environmental conditions, e.g., obesity, converge on Yes-associated protein (YAP) and WW-domain-containing transcriptional co-activator with PDZ-binding motif (TAZ), transcriptional co-activators in the Hippo pathway. Statins and metformin, widely used Food and Drug Administration-approved drugs, show great promise to intercept this disease by disrupting or inhibiting this amplifying network at multiple points converging onto YAP/TAZ.
